Remibrutinib results in significant improvement in patients still symptomatic after second-generation H1-antihistamine treatment.

Morgan Stanley backs Celldex Therapeutics for growth with barzolvolimab's market-leading potential in chronic urticaria. Read ...

A recent survey found an average loss of 62% of bee colonies among commercial operations in less than a year. Causes and ...

Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome ...

Karishmma Chawla, a Functional Medicine & Lifestyle Educator, explains, “Food is the most intimate part of our body. It ...

Cash Position & Operating Runway: As of December 31, 2024, ARS Pharma had cash, cash equivalents, and short-term investments ...

The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted ...

A migraine attack is more than a headache. It can derail your entire day.

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...

The cause of rashes can vary, spanning allergic reactions, infections, autoimmune diseases and environmental irritants.